Biogen, Inc.

Biogen, Inc.

Biogen, Inc.

Overview
Date Founded

1997

Headquarters

5200 Illumina Way, San Diego, CA, 92122, US

Type of Company

Public

Employees (Worldwide)

7,800

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals
Medical Support Services

Company Description

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Biogen, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Executive Vice President & Chief Financial Officer

Senior Vice President & Chief Information Officer

Senior Vice President & Chief Information Officer

Executive Vice President, Chief Legal Officer & Secretary

Executive Vice President & Chief Medical Officer

Chief Human Resources Officer & Executive Vice President

Chief Accounting Officer & Vice President

General Manager

Executive Vice President, Research & Development

Board of Directors

Co-Founder at Exelixis, Inc.

Founding Partner at Sarissa Capital Management LP

Former Chief of Staff at California Office of the Governor, Gray Davis

Senior Advisor at EW Healthcare Partners

Director of the Harvard Gene Therapy Initiative at Harvard University - Harvard Medical School

Venture Partner at Third Rock Ventures LLC

Founder at Point Rider Group LLC

Fund Advisor at Goldman Sachs Asset Management LP

Executive Chairman at Rgenix, Inc.

Co-Founder at Ivy Capital Partners LLC

Paths to Biogen, Inc.
Potential Connections via
Relationship Science
You
Biogen, Inc.
Owners & Shareholders
Details Hidden

PRIMECAP invests primarily common stocks or securities with common stock characteristics, bonds and cash/cash equivalents. The firm utilizes fundamental research and bottom-up stock picking to construct portfolios. The main sources of information for research purposes include financial publications, inspections of corporate activities, research materials by others such as sell-side analysts, companies' annual reports and any related filings and press releases, meetings with executives of companies and their suppliers, competitors, customers, etc. All portfolios are built with the best ideas of each of the managers within the multi-manager investment process. PRIMECAP's investment strategy does not employ short sales or margin transactions, nor does it permit investments in derivatives or currency hedging. The firm follows an investment approach based on four key principles including commitment to fundamental research, long-term investment horizon, emphasis on individual decision-making and focus on value.

Details Hidden

ClearBridge Investments offers strong leadership, seasoned Portfolio Managers, and a well-resourced, centralized investment infrastructure operating from offices in New York and San Francisco. We benefit from the formidable strength of the Legg Mason organization, while continuing to operate with investment independence — maintaining our own investment strategies, philosophies and investment decision-making authority. ClearBridge currently has over 158 employees, including more than 54 investment professionals.

Details Hidden

AQR specializes in quantitative investment analysis. The firm's models may consider a wide breadth of factors - from traditional valuation measures, momentum indicators, and price signals, to textual analysis of financial reporting and terms of trade information. They perform their research internally. AQR begins the process of building a model to test the strategy's viability once an investment approach is identified. The model building process generally consists of two steps: (1) designing an investing strategy to implement the given approach; and (2) producing testable implications. They perform ongoing research to monitor and maintain the effectiveness of its models over time. In developing quantitative forecasting computer models, they use external data. AQR may also utilize discretionary and/or hybrid strategies through a combination of quantitative and fundamental techniques. They utilize several investment strategies including, but not limited to, arbitrage strategies, equity strategies, global macro strategies, fixed income strategies, and risk parity.

Recent Transactions
Details Hidden

purchases Bioverativ, Inc. from Biogen, Inc.

Details Hidden

Brammer Biopharmaceuticals LLC purchases Biogen, Inc. /Biomanufacturing Plant from Biogen, Inc.

Details Hidden

Biogen, Inc. purchases Eisai, Inc. /North Carolina Plant from Eisai Co., Ltd.

Transaction Advisors
Legal Advisor

Advised on purchases Bioverativ, Inc. from Biogen, Inc.

Investment Advisor

Advised on purchases Bioverativ, Inc. from Biogen, Inc.

Legal Advisor

Advised on purchases Bioverativ, Inc. from Biogen, Inc.

Advisors & Consultants
Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Advisor

Executive Vice President & Chief Financial Officer at Alexion Pharmaceuticals, Inc.

Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Clients

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company is headquartered in Chesterbrook, PA.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2018
Market Capitalization
$43.9B
Total Enterprise Value
$64.2B
Earnings Per Share
$21.58
Revenue
$12.1B
Net Profit
$4.43B
Total Debt
$5.94B
Total Equity
$13B
Debt TEV
0.09x
Enterprise Value Sales
5.32x
TEVNet Income
14.48x
Enterprise Value EBITDAOperating
11.04x
EBITDAMargin
48.23%
EBITDA
$5.81B
Three Year Compounded Annual Growth Rate Of Revenue
8.95%
Five Year Compounded Annual Growth Rate Of Revenue
15.51%
Non-Profit Donations & Grants
Political Donations
$1,500
2002
Investments
Details Hidden

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.

Details Hidden

Yumanity Therapeutics, Inc. engages in transforming drug discovery for neurodegenerative diseases services. It provides integrated discovery platforms, phenotypic screening (uHTS) platforms, in which different protein misfolding pathologies are modeled in yeast to help discover compounds to correct these pathologies; a human neuronal platform. The company was founded by Anthony N. Coles, Jr. and Susan L. Lindquist in December 2014 and is headquartered in Cambridge, MA.

Details Hidden

Rodin Therapeutics, Inc. develops first in class therapeutics for cognitive disorders. The company was founded by Bruce Booth in 2013 and is headquartered in Cambridge, MA.

Suppliers
Acorda Therapeutics, Inc. Pharmaceuticals | ARDSLEY, NY

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

PDL BioPharma, Inc. Medical Support Services | Incline Village, NV

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. The Pharmaceutical segment covers revenues from branded prescription medicine products being sold under the name Tekturna and Tekturna HCT in the United States, and Rasilez and Rasilez HCT for the rest of the world. The Medical Devices segment handles revenues from the LENSAR Laser System sales. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Boston Properties, Inc. Trusts & Funds | Boston, MA

Boston Properties, Inc. operates as a real estate investment trust. It develops, redevelops, acquires, manages, and owns aportfolio of Class A properties. It operates through the following geographical segments: Boston, New York, San Francisco, and Washington, DC. The company was founded by Mortimer Benjamin Zuckerman and Edward H. Linde in 1970 and is headquartered in Boston, MA.

Competitors
Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Teva Pharmaceutical Industries Ltd. Pharmaceuticals - Petach Tikva, HM

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Bayer AG Pharmaceuticals - Leverkusen, NW

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and acts as a socially and ethically responsible corporate citizen. In fiscal year 2012, Bayer employed 110,500 people and had sales of €39.8 billion. Capital expenditures amounted to €2 billion, R&D expenses to €3 billion.

Awards & Honors
Rank #263
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #263
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Biogen, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Biogen, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Biogen, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/biogen-inc-22216
  • https://relationshipscience.com/organization/biogen-inc-22216